Scienceblogtwo

The liver is a crucial organ in the body's processing of all the many substances we put into it, including food, drink, alcohol, and narcotics. When the liver malfunctions, the results might be fatal. Scarring, also known as liver fibrosis, is the primary cause of many liver illnesses, including hepatitis and Non-Alcoholic SteatoHepatitis, or NASH. At this time, there are no medications available to cure this scarring. In order to find possible targets for medications in the future, researchers are looking into the underlying causes of liver fibrosis. A chemical responsible for the bile duct cells' unchecked proliferation inside the liver has been identified by a U-M study. The bile duct cells are injured in diseased livers, according to Liangyou Rui, Ph.D., the Louis G. D'Alecy Collegiate Professor of Physiology. The liver must constantly produce new bile duct cells, but occasionally these cells malfunction, resulting in inflammation and scarring. Rui notes that this incre...

The Tob gene, which was initially discovered at Prof. Tadashi Yamamoto's old group in Japan in 1996, is well known for its connection to cancer. Previous studies have shown that it also plays a role in controlling the cell cycle and the immunological response of the body. Now, scientists from the Okinawa Institute of Science and Technology (OIST) have discovered that this gene also has a significant role in lowering depression, fear, and anxiety in a multidisciplinary study that blends molecular biology with neuroscience. The Translational Psychiatry journal published their research. Lead author Dr. Mohieldin Youssef, a former PhD candidate in Prof. Yamamoto's Cell Signal Unit at OIST, stated that the study's focus was on understanding stress-resilience. The gene contributes to stress resilience when it is present, while depression, fear, and anxiety rise when it is not. The Japanese verb "tobu," which means to soar or jump, inspired the name "Tob." This...

The study, which took advantage of the plasticity of the emerging neural networks in the developing teenage brain, provides optimism that the therapy is successfully reactivating brain-retinal communication channels that had remained dormant. Academic research has been conducted to determine whether the medicine is changing the brain circuits specific to the cones in conjunction with a phase 1/2 clinical study in children with achromatopsia. Achromatopsia is caused by one or a few genes having disease-causing mutations. It has an impact on cone cells, one of the two types of photoreceptors in the eyes (the other being rods). Because cones are crucial for color vision, people with achromatopsia are completely colorblind in addition to having very poor overall vision and finding bright light painful (photophobia). Since the dormant cone cells exist but do not send messages to the brain, researchers are working to revive them. "Our study is the first to directly confirm popular belie...

The CRISPR genome editing technique is incredibly efficient but not necessarily secure, the researchers warn. Sometimes cleaved chromosomes do not regrow, compromising genomic stability, which over time might support cancer. According to recent research from Tel Aviv University, using CRISPR therapeutics, a breakthrough, Nobel Prize-winning approach that entails cleaving and editing DNA, to treat ailments including cancer, liver, and intestinal disorders, and genetic abnormalities, has risks. Up to 10% of the treated T-cells, which are white blood cells in the immune system, had genetic material destroyed, according to research on how this procedure affected them. They clarify that such loss might cause the genome to become unstable, which might cause cancer. The Tel Aviv Sourasky Medical Center (Ichilov) and Tel Aviv University collaborated on the study, which was led by Dr. Adi Barzel of TAU's Wise Faculty of Life Sciences and Dotan Center for Advanced Therapies, as well as Drs. ...

Genetic Testing May Benefit Individuals A recent study by the U.S. Department of Veterans Affairs suggests that pharmacogenomic testing could help doctors avoid prescribing prescription antidepressants that might have negative side effects. Pharmacogenomics investigates how genetics affect how the body responds to medications. The study also found that patients who underwent genetic testing performed better than those receiving standard care. Over the course of the treatment's 24 weeks, the genetic testing group experienced a decrease in depression symptoms, with a peak effect at week 12. Each study subject experienced a severe depressive condition. The illness manifests as insomnia, an appetite loss, a gloomy mood, and suicidal thoughts. Dr. David Oslin, director of the VA's VISN 4 Mental Illness, Research, Education, and Clinical Center, oversaw the study (MIRECC). He thinks the results will persuade medical professionals to consider using pharmacogenomic testing to inform tr...